Overview of Orlica

Property	Description
Active ingredient	Orlistat
Form	Hard Capsule
Pharmacological class	Lipase Inhibitor, Peripherally Acting Anti-Obesity Agent
Common use	Obesity management, long-term weight maintenance
Origin	Synthetic organic compound (derived from lipstatin)

Defining Orlica: Type and Classification of the Agent

Orlica is a medication specifically utilized for obesity management and weight maintenance, with its active ingredient being the compound Orlistat. Pharmacologically, Orlistat is classified as a Lipase Inhibitor and a Peripherally Acting Anti-Obesity Product. This classification means the drug's effect is localized and occurs entirely within the gastrointestinal tract, a mechanism that has been clinically recognized as eliminating the central nervous system effects associated with some older weight-loss medications. Orlistat works by inhibiting the absorption of dietary fats. The medicine acts only on the food you eat, not on the body's appetite or brain chemistry.

Composition, Form, and Origin: Orlistat as a Single-Ingredient Product

The preparation is provided as a single-ingredient product formulated as a hard capsule for oral administration. The active substance, Orlistat, is a synthetic organic compound derived from lipstatin, a natural product found in the bacterium Streptomyces toxytricini. This specific synthesis ensures a consistent, stable compound suitable for pharmaceutical preparation. Orlistat is highly selective and has marginal effects on other types of hydrolytic enzymes. This suggests its action is precise and limited only to the fat-digesting enzymes in the gut, a key differentiating factor from non-selective digestive aids.

General Therapeutic Purpose: The Role in Weight Management

The primary purpose of Orlica is to assist in Body Mass Index (BMI) reduction by effectively limiting the absorption of fat calories from meals. Orlistat achieves this by acting as a specific inhibitor of gastric and pancreatic lipases, enzymes required for the digestion of large fat molecules. By preventing the breakdown of these dietary fats into absorbable components, it causes a measurable reduction of dietary fat absorption, directly supporting the overarching goal of chronic weight management when combined with necessary dietary adjustments. A typical use scenario involves its prescribed inclusion as part of a comprehensive program for patients facing long-term weight challenges.

Therapeutic Uses of Orlica

What Orlica Treats: Main Uses and Benefits

Orlica is primarily used in the management of obesity and overweight. It is commonly used to help with managing excess body weight and supporting long-term maintenance. This therapy is commonly applied in clinical settings that involve chronic weight challenges within established clinical criteria, often for patients with a high Body Mass Index (BMI ge 30 kg/m^2) or those with a lower BMI (typically ge 27 kg/m^2) who present with associated health risks.

Therapeutic Support in Weight Management

Orlica is commonly used to help with managing excess body weight and to address systemic imbalance in patients with weight-related comorbidities like high blood pressure or dyslipidemia. Orlica provides a relevant form of support during phases when symptoms of chronic weight management become more noticeable, particularly symptoms related to episodic or fluctuating manifestations of weight. It contributes to easing the overall symptom load related to high BMI and may assist with maintaining functional stability.

“This support helps patients cope more steadily with the long-term clinical context of managing sustained weight reduction.”

Clinical Indications and Patient Benefit

Orlica is considered relevant across three key therapeutic areas: managing obesity, managing overweight in conditions where symptoms may intensify temporarily, and providing support for sustained weight loss maintenance. By supporting the reduction of body weight, it may assist with managing symptoms related to metabolic and cardiovascular stress that create noticeable physiological strain, and may contribute to supporting general well-being during symptomatic phases.

Quick Fact: Relevant for conditions involving Sustained Weight Management

Regulatory References

NIH MedlinePlus overview

Eligibility and Restrictions for Use

The eligibility for Orlica (Orlistat) is strictly defined by regulatory authorities and centers on population status, age, and pre-existing medical conditions.

Eligibility Status	Patient Group/Condition
Approved for Use	Adults and adolescents ge 12 years of age who meet specific body mass index (BMI) criteria for obesity management.
Contraindicated Use	Patients with Chronic Malabsorption Syndrome, Cholestasis (impaired bile flow), Known Hypersensitivity to Orlistat, Pregnancy, and Breastfeeding.

Age and Condition Restrictions

Safety and efficacy have not been established for the pediatric population under 12 years of age, and use is not recommended for this group. Conditional use requires medical caution for patients with a history of Kidney Stones (nephrolithiasis), pre-existing Kidney Disease, or underlying Liver Disease. Furthermore, patients being treated with certain medications, such as Cyclosporine, face restricted eligibility as stated in the official prescribing information. The regulatory labeling thus strictly defines the permitted user pool.

What should I know about interactions with other medicines?

The official regulatory profile for Orlica is characterized by pharmacokinetic interactions that result in the impaired absorption of specific lipophilic co-administered substances in the gastrointestinal tract. This absorption interference dictates the profile's restrictions and requirements for timing separation.

Classification	Interacting Substances/Categories
Contraindicated	Ciclosporin; Oral Anticoagulants (e.g., Warfarin)
Exposure Reduction	Levothyroxine, Antiretroviral and Antiepileptic Medicinal Products
Nutrient Impact	Fat-soluble Vitamins (A, D, E, K and Beta-Carotene)

Co-administration with Ciclosporin is formally restricted in certain regulatory regions due to a decrease in its plasma levels, which risks compromising immunosuppressive efficacy. Similarly, the use of oral anticoagulants like Warfarin is restricted due to the potential for altered International Normalized Ratio (INR) values stemming from reduced Vitamin K absorption.

Mandatory administration timing rules are documented to mitigate reduced absorption. Levothyroxine must be administered at least 4 hours apart from Orlica, while Ciclosporin requires a separation of at least 3 hours. Multivitamin supplements containing fat-soluble vitamins must be taken at least 2 hours apart or at bedtime. For patients with diabetes, close monitoring of antidiabetic drug treatment is required upon initiating Orlica therapy. The risk of gastrointestinal symptoms may increase when Orlica is taken with a high-fat meal.

Mechanism of Action

Covalent Inhibition of Digestive Lipase Enzymes

Orlica’s mechanism is defined by the direct, local engagement of gastric and pancreatic lipases, the enzymes critical for fat digestion. The active ingredient forms a stable, covalent bond with the active site's serine residue, permanently inactivating these enzymes. This action prevents the hydrolysis of dietary triglycerides into absorbable free fatty acids, ensuring the fat molecules remain intact in the gastrointestinal lumen.

Modulation of Systemic Energy Balance via Peripheral Action

The functional consequence of blocked fat digestion is that a defined portion of undigested fat cannot be absorbed across the intestinal wall and is instead excreted in the feces. This peripheral action, which is confined entirely to the gastrointestinal lumen and avoids central nervous system pathways, results in a quantifiable and sustained reduction in net caloric absorption from the meal. This change contributes to a systemic energy deficit.

Mechanism Constraints and Lipophilic Dynamics

The drug's action is strictly dependent on dietary fat as a substrate. The resulting high concentration of unabsorbed fat in the gut is associated with a change in the absorption dynamics of other lipophilic molecules, including vitamins A, D, E, and K.

Dosage and Administration Information

Orlica is administered exclusively via the oral route using a hard capsule formulation. The standard dosing regimen is one capsule, taken three times per day, with the prescription strength being 120 mg and a lower strength available at 60 mg. The maximum recommended daily dose is 360 mg.

Administration of the capsule is strictly linked to food intake. The dose must be taken immediately before, during, or up to one hour after each main meal that contains fat. If a meal is missed or contains no fat, the corresponding dose of Orlica must be omitted, as the drug's action is conditional on the presence of fat in the gastrointestinal tract.

The use of Orlica is required to be integrated into a comprehensive program that includes a nutritionally balanced, reduced-calorie diet. This diet should ensure that the daily intake of fat, carbohydrate, and protein is distributed across the three main meals. Due to the drug's official use constraints, the daily intake of a fat-soluble multivitamin supplement (Vitamins A, D, E, and K) is required. This supplement must be administered at least two hours apart from the Orlica dose, or at bedtime.

Regarding specific populations, the 120 mg dose is officially approved for use in adolescents aged 12 years and older. For adults, therapy continuation is formally assessed based on results; clinical criteria specify that 120 mg treatment should be discontinued if the patient has not achieved at least 5% weight loss within 12 weeks of initiating therapy.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Clinical Findings

Research evaluated the drug's pharmacological action. Studies investigated the results of a combination with Therapy Z.

Key Study Results

One study of 50 patients evaluated the drug's effects on joint flexibility and the measurement of stiffness. The drug was evaluated across different demographics in the study.

Assessment Area	Research Focus
Dosing	Studies examined a dose of 10mg daily and assessed measurements of symptoms over time.
Study Population	The study population included individuals with kidney issues.
Comparison	Studies compared this drug to older treatments and assessed the magnitude of the observed effect.

Safety and Tolerability Profile

Studies recorded side effects and recorded their characteristics. The study design included evaluation of co-administration with alcohol.

Frequently Asked Questions (FAQ)

Common questions about Orlica (FAQ)

Q: How does Orlica differ from other similar medicines I see advertised?

The official product information classifies this medicine as a Peripherally Acting Anti-Obesity Product and a Lipase Inhibitor. This means its mechanism of action is limited only to the digestive tract, where it prevents the absorption of fat. It does not work by affecting the brain or central nervous system.

Q: Are the side effects of Orlica generally temporary or long-term?

Studies and official information indicate that the incidence of gastrointestinal-related side effects, which are the most common, generally decreases over time. The rate of these effects was shown to be lower after the first year of treatment and with continued use.

Q: What kind of foods or drinks should be avoided while taking Orlica?

While no specific foods are strictly prohibited, the medicine is designed to work by blocking fat absorption. Taking Orlica with a meal that is excessively high in fat may increase the likelihood of experiencing gastrointestinal side effects.

Q: Do I need to take Orlica at the exact same time every day?

The dose is linked to food intake, not a specific clock time. Official administration rules describe that the medicine is to be taken with water immediately before, during, or up to one hour after each main meal that contains fat.

Q: How is the effectiveness of Orlica measured in research studies?

Effectiveness in clinical trials is generally measured by comparing the amount of weight lost by patients taking the medicine versus those taking a placebo. A key regulatory benchmark is the percentage of patients who achieve a weight loss of at least 5% of their starting body weight within a 12-week period.

Q: What are the major findings from the clinical trials for Orlica?

Official clinical findings indicate that patients taking the medicine achieved greater average weight loss when compared to those taking a placebo. A higher percentage of patients also achieved the clinically significant goal of 5% or more weight loss.

Q: Why is Orlica considered a specialized treatment?

It is considered specialized because of its highly specific mechanism of action: it selectively and locally blocks fat-digesting enzymes in the gut. This peripheral action is distinct from other older weight-loss products that may have targeted the central nervous system.

Q: What is the average duration of treatment with Orlica?

The official recommended maximum duration for the over-the-counter 60 mg strength is six months. The 120 mg prescription strength has been evaluated in long-term studies that followed patients for up to four years for chronic weight management.

Q: Are there any known interactions between Orlica and alcohol?

Official regulatory documents and interaction studies have stated that no interactions between this medicine and alcohol have been observed.

Q: Is Orlica available over the counter, or is it prescription only?

The medicine is available in two different strengths. A higher strength (120 mg) is generally available only by prescription, while a lower strength (60 mg) is sold over the counter in many regions.

Q: Does Orlica affect birth control pills or other hormonal medications?

Specific interaction studies observed no change in the ovulation-suppressing action of oral contraceptives. However, official labeling includes a precaution that if severe diarrhea occurs, the use of an additional non-oral method of contraception may be necessary to maintain efficacy.

Q: What happens if I stop taking Orlica suddenly?

Regulatory information indicates that the therapeutic effect is temporary. The content of undigested fat in the feces, which is how the drug’s action is measured, typically returns to pre-treatment levels within 48 to 72 hours of discontinuation.

Q: I read that Orlica has a 'Black Box Warning'—what does that mean for me?

The medicine does not currently feature a Black Box Warning in its official regulatory labeling. However, government authorities have completed safety reviews regarding rare postmarketing reports of severe liver injury and hepatic failure.

Q: What is the difference between the brand name and a generic version of Orlica?

The difference often lies in the strength and availability. The brand name includes both a 120 mg prescription-strength and a 60 mg over-the-counter strength. Generic versions are also available in the 120 mg prescription strength.

Q: Does Orlica contain any ingredients I should be aware of for allergies (e.g., lactose, gluten)?

The official product information details a list of excipients (non-active ingredients) in the capsule, which can include microcrystalline cellulose, talc, and povidone. Some versions may contain lactose, meaning individuals with severe lactose intolerance should check the specific formulation.

Q: Is Orlica a habit-forming or addictive medication?

No. The medicine is not classified as a controlled substance and is not considered a habit-forming or addictive medication by regulatory authorities.

Q: Is there a maximum time someone can safely take Orlica?

Official documents recommend the 60 mg over-the-counter strength be used for a maximum of six months. For the 120 mg prescription strength, studies followed patients for up to four years, indicating its role in long-term weight management.

Q: Does Orlica cause hair loss or changes in skin?

The medicine’s safety profile includes rare postmarketing reports of adverse skin reactions, such as hypersensitivity symptoms and cutaneous vasculitis (inflammation of blood vessels in the skin). Hair loss is not listed in the main adverse reaction classifications.

Q: How quickly does Orlica leave the system after the last dose?

The half-life of the small amount of the drug that is absorbed by the body is relatively short, usually 1 to 2 hours. The main effect—the increase of undigested fat in the stool—returns to pre-treatment levels within 48 to 72 hours after the last dose.

Q: How does Orlica compare to placebo in clinical trials?

In clinical trials, the prescription strength of the medicine demonstrated superior results when compared to placebo. For instance, in one study, approximately 57% of patients taking the drug achieved a loss of 5% or more of their body weight, compared to 31% of patients on placebo.

Q: Does Orlica affect the results of other lab tests?

The drug is known to reduce the absorption of fat-soluble vitamins (A, D, E, K), which can be reflected in lab tests. Due to the potential for reduced Vitamin K absorption, regulatory documents specify that patients taking certain blood thinners should have their blood clotting parameters, such as INR, closely monitored.

How should Orlica be stored and disposed of?

How to Store and Dispose of Orlica

The storage of Orlica (orlistat 120 mg capsules) must strictly comply with official regulatory guidelines to maintain stability. The medicine must be kept out of the sight and reach of children.

Storage Requirements

Condition	Requirement (Official Labeling)
Temperature	Store below 25 C (blister) or 30 C (bottle). Do not freeze.
Protection	Keep protected from heat, moisture, and light in a dry place.
Container	Store in the original package; keep glass bottles tightly closed.

Disposal Instructions

Unused or expired Orlica must not be disposed of via wastewater or household waste. The medicine must be discarded according to local regulations. Patients should consult their pharmacist or local waste management company for instructions on proper disposal.

Orlica